Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Invivyd, Inc.IVVD · Entity 721 | 10% owner | January 19, 2024 | January 22, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Invivyd, Inc.
Report date January 19, 2024 · Filed January 22, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,687,906 |
Reported balance
After 2024-01-19 transaction · row 1
1 source rowRow 1 · 2024-01-19 · Sale · Disposed 5,000,000 · Balance 21,687,906 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 19, 2024 Filed Jan 22, 2024 16:18 UTC | Invivyd, Inc. IVVD · Entity 721 | SaleCommon Stock | 5,000,000 | $3.95 | $19,750,000.00 |
DisclosureSEC source: 0000950170-24-006070 · ownership.xml · nonDerivative · entry 1 Adimab, LLC · CIK 0001545672 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,687,906 Read SEC document |
| March 03, 2022 Filed Apr 1, 2022 16:08 UTC | Invivyd, Inc. ADGI · Entity 721 | OtherCommon Stock | 1,158,089 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-013098 · doc4.xml · nonDerivative · entry 1 Adimab, LLC · CIK 0001545672 · 10% owner · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,687,906 F1 · kind: In connection with the resignation of Dr. Tillman Gerngross from the Issuer's Board of directors, the Issuer repurchased 1,158,089 shares of restricted common stock from the Reporting Person for aggregate consideration of $2,316.18. F1 · price: In connection with the resignation of Dr. Tillman Gerngross from the Issuer's Board of directors, the Issuer repurchased 1,158,089 shares of restricted common stock from the Reporting Person for aggregate consideration of $2,316.18. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 21:22 UTC | Invivyd, Inc. ADGI · Entity 721 | ConversionSeries C Preferred Stock · Derivative | 128,064 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-051295 · doc4.xml · derivative · entry 4 Adimab, LLC · CIK 0001545672 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 640,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 21:22 UTC | Invivyd, Inc. ADGI · Entity 721 | ConversionSeries B Preferred Stock · Derivative | 44,076 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-051295 · doc4.xml · derivative · entry 3 Adimab, LLC · CIK 0001545672 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 220,380 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 21:22 UTC | Invivyd, Inc. ADGI · Entity 721 | ConversionSeries A Preferred Stock · Derivative | 5,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-051295 · doc4.xml · derivative · entry 2 Adimab, LLC · CIK 0001545672 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 21:22 UTC | Invivyd, Inc. ADGI · Entity 721 | ConversionCommon Stock | 25,860,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-051295 · doc4.xml · nonDerivative · entry 1 Adimab, LLC · CIK 0001545672 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,845,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.